SCHEMBL3359569

SCHEMBL3359569

CN1CCCC(O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10217 1.00
SCHEMBL10796 1.00
SCHEMBL685385 1.00
Water SCHEMBL27587846 0.97 CA12 (0.42)
Ethane SCHEMBL7360363 0.97 CA12 (0.42)
Methane SCHEMBL3247537 0.97
Hydrochloric Acid SCHEMBL31732955 0.97
Hydrochloric Acid SCHEMBL27149835 0.97
SCHEMBL24086950 0.92
SCHEMBL15495008 0.92

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149648-A1 NUCLEOTIDE ANALOGS GILEAD SCIENCES, INC. (US) 2009-06-11 US claimed
US-7439350-B2 Nucleotide analogs GILEAD SCIENCES, INC. (US) 2008-10-21 US claimed
US-6225460-B1 PHOSPHOAMIDATE OR ESTER BOND THAT IS HYDROLYZED IN VIVO TO YIELD A CORRESPONDING PHOSPHONATE NUCLEOTIDE ANALOG. GILEAD SCIENCES, INC. 2001-05-01 US claimed
US-5656745-A AMIDATE LINKAGE; ANTITUMOR, ANTICARCINOGENIC AGENTS GILEAD SCIENCES, INC. (US) 1997-08-12 US claimed
EP-2912178-B1 SUPER-ENHANCERS AND METHODS OF USE THEREOF WHITEHEAD INST BIOMEDICAL RES (US) 2020-06-17 EP disclosed
US-10160977-B2 Super-enhancers and methods of use thereof WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2018-12-25 US disclosed
US-20160237490-A1 SUPER-ENHANCERS AND METHODS OF USE THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 2016-08-18 US disclosed
US-9181580-B2 Super-enhancers and methods of use thereof WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2015-11-10 US disclosed
US-9155724-B2 Combination methods for treatment of disease WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2015-10-13 US disclosed
US-20150111761-A1 SUPER-ENHANCERS AND METHODS OF USE THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 2015-04-23 US disclosed
US-20140296218-A1 SUPER-ENHANCERS AND METHODS OF USE THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2014-10-02 US disclosed
US-20140287932-A1 SUPER-ENHANCERS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-09-25 US disclosed
US-20130053415-A1 COMBINATION METHODS FOR TREATMENT OF DISEASE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-02-28 US disclosed
EP-0719273-B1 NUCLEOTIDE ANALOGS GILEAD SCIENCES INC (US) 2010-11-03 EP disclosed
US-20090149648-A1 NUCLEOTIDE ANALOGS GILEAD SCIENCES, INC. (US) 2009-06-11 US disclosed
US-7439350-B2 Nucleotide analogs GILEAD SCIENCES, INC. (US) 2008-10-21 US disclosed
US-6225460-B1 PHOSPHOAMIDATE OR ESTER BOND THAT IS HYDROLYZED IN VIVO TO YIELD A CORRESPONDING PHOSPHONATE NUCLEOTIDE ANALOG. GILEAD SCIENCES, INC. 2001-05-01 US disclosed
US-5798340-A ANTITUMOR/ANTINEOPLASTIC ACTIITY, VIRICIDES; BROAD SPECTRUM MICROBIOCIDES; THIOPHOSPHONATES HYDROLYZABLE IN VIVO; ORAL ADMINISTRATION; BIOAVAILABILITY; NONTOXIC; POTENCY GILEAD SCIENCES, INC. (US) 1998-08-25 US disclosed
EP-0719273-A1 NUCLEOTIDE ANALOGS GILEAD SCIENCES, INC. (US) 1996-07-03 EP disclosed
WO-1995007920-A1 NUCLEOTIDE ANALOGS GILEAD SCIENCES, INC. (US) 1995-03-23 WO disclosed